VBL Therapeutics to Report Fiscal 2017 Results on March 15

VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, March 15 at 8:30am Eastern Time to report fiscal year ended December 31, 2017 financial results.

Thursday, March 15th @ 8:30am Eastern Time
Domestic:	877-222-6394
International:	703-925-2702
Conference ID:	7392936
Webcast:	https://edge.media-server.com/m6/p/y3srj89d
Replays, Available through March 29th:
Domestic:	855-859-2056
International:	404-537-3406
Conference ID:	7392936

About VBL  Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and demonstrated efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 trial for platinum-resistant ovarian cancer.

INVESTOR CONTACT:Michael RiceLifeSci Advisors, LLC(646) 597-6979

MEDIA CONTACT:Matt Middleman, M.D.LifeSci Public [e-mail][phone]